Hypertensive treatment in older adults with vascular brain lesions: should we SPRINT faster?
- Conditions
- Hypertension<br />Cerebral Small Vessel Disease (CSVD)<br /><br />Hypertensie <br />Cerebrale wittestofschade
- Registration Number
- NL-OMON24551
- Lead Sponsor
- VU University Medical Centre
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- Not specified
- Target Recruitment
- 20
Inclusion Criteria
• ≥ 65 years of age
• High systolic blood pressure of 150-200mmHg based on the average of a daytime 24-hour BP (with or without taking antihypertensive medication)
Exclusion Criteria
• Medical history of diabetes mellitus
• Experienced myocardial infarction within the past 12 months
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method cerebral blood flow velocity
- Secondary Outcome Measures
Name Time Method cognitive functioning, white matter lesions, orthostatic hypotension, dynamic cerebral autoregulatory capacity, CO2 responsiveness, experienced side effects, disability to reach assigned BP target
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms link hypertension management to cerebral small vessel disease progression in elderly patients?
How does intensive blood pressure control compare to standard therapy in preventing CSVD-related outcomes in older adults?
Which biomarkers are associated with response to antihypertensive treatment in cerebral small vessel disease patients?
What adverse events are commonly observed in elderly patients undergoing aggressive hypertension therapy for CSVD?
Are there combination therapies or alternative drug classes showing promise for treating hypertension-induced vascular brain lesions?